1 / 3

Abemaciclib

Boc Sciences offers 1231929-97-7 Abemaciclib in bulk, please inquire us to get a quote for 1231929-97-7 Abemaciclib.<br>https://www.bocsci.com/abemaciclib-cas-1231929-97-7-item-462724.html<br>

bocsci2018
Download Presentation

Abemaciclib

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Abemaciclib - CAS 1231929-97-7 Catalog number: B0084- 462724 Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers. Please be kindly noted that our product can only be used for research to orgnizations or companies and we don't cooperate with personal buyers. Category Inhibitor Targets CDK SARS-CoV-2 Molecular Formula C27H32F2N8 Molecular Weight 506.61 Ordering Information Catalo g Numbe r Siz e Pric e Stoc k Quantity B0084- 462724 100 mg $188In stock 0 Bulk Inquiry Add to cart Chemical Information Category Inhibitor

  2. Molecular Formula C27H32F2N8 Molecular Weight 506.61 Specification Properties Reference Reading    Purity ≥98% Related CAS 1231930-82-7 (mesylate) Appearance Light Yellow Solid Synonyms LY-2835219; LY 2835219; LY2835219; Verzenio; N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-y l]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Clinical Trial Information NCT Number Title Condition Or Disease Phase Start Date Sponsor Status NCT01394016A Phase 1 Study of LY2835219 In Participants With Advanced Cancer Advanced Cancer Phase 1 December 7, 2009 Eli Lilly and Company Active, not recruiting NCT01655225A Study of LY3023414 in Participants With Advanced Cancer Advanced Cancer Phase 1 July 31, 2012 Eli Lilly and Company Recruiting NCT01739309Study of LY2835219 for Mantle Cell Lymphoma Mantle Cell Lymphoma Phase 2 March 2013 Eli Lilly and Company Active, not recruiting NCT02014129A Study of LY2835219 in Japanese Participants With Advanced Cancer Neoplasm Metastasis Phase 1 December 2013 Eli Lilly and Company Active, not recruiting

  3. NCT02057133A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread Breast Neoplasms Phase 1 March 10, 2014 Eli Lilly and Company Recruiting Preparing Stock Solutions ConcentrationVolumeMass 1 mg 5 mg 10 mg 1 mM 1.9740 mL 9.8699 mL 19.7398 mL 5 mM 0.3948 mL 1.9740 mL 3.9480 mL 10 mM 0.1974 mL 0.9870 mL 1.9740 mL 50 mM - - - https://www.bocsci.com/abemaciclib-cas-1231929-97-7-item-462724.html

More Related